Search Results

Your search for Jeff Summers, MD, and Marc R. Theoret, MD,Jeff Summers, MD, and Marc R. Theoret, MD matches 2 pages

Showing 1 - 2

By Julie A. Schneider, PhD; Jennifer J. Gao, MD; Martha B. Donoghue, MD; Lola Fashoyin-Aje, MD, MPH; Jeff Summers, MD; Paul G. Kluetz, MD; Marc R. Theoret, MD; and Richard Pazdur, MD / February 10, 2023

FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities

OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...

issues in oncology

By Jeff Summers, MD, and Marc R. Theoret, MD / January 25, 2022

Project Catalyst: Educating Industry to Help Develop Successful Cancer Therapies

OCE Insights is written by members of the Oncology Center of Excellence (OCE) and the Office of Oncology Diseases (OOD) at the U.S. Food and Drug Administration. In this installment, Jeff Summers, MD, OOD Acting Associate Director for Translational Sciences, and Marc R. Theoret, MD, OCE Deputy...

Nov

Today In Oncology

Search Results

Your search for Jeff Summers, MD, and Marc R. Theoret, MD,Jeff Summers, MD, and Marc R. Theoret, MD matches 2 pages

FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities

Project Catalyst: Educating Industry to Help Develop Successful Cancer Therapies

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC